ライフサイエンスコーパス: adeno-associated

1 siRYR2-U10), we evaluated the efficacy of an adeno-associated serotype 9 viral vector (AAV9) expressi

2 e potential utility of a novel combinatorial adeno-associated viral (AAV) gene therapy by expressing

3 ium (RPE) of Mfrp (rd6) /Mfrp (rd6) mice via adeno-associated viral (AAV) gene therapy.

4 gene therapy approach using liver-directed, adeno-associated viral (AAV) serotype 8 vector delivery

5 We infused a single-stranded adeno-associated viral (AAV) vector consisting of a bioe

6 eived bilateral infusions of a Cre-dependent adeno-associated viral (AAV) vector expressing enhanced

7 ccessful clinical data on gene therapy using adeno-associated viral (AAV) vector for hemophilia B (HB

8 We have used an adeno-associated viral (AAV) vector to deliver the genes

9 We further injected an adeno-associated viral (AAV) vector to express IVS-AAA i

10 Rho specific transcriptional silencing upon adeno-associated viral (AAV) vector-mediated expression

11 Use of adeno-associated viral (AAV) vectors for liver-directed

12 Gene replacement therapies utilizing adeno-associated viral (AAV) vectors hold great promise

13 When using adeno-associated viral (AAV) vectors to express lucifera

14 In this study, we use adeno-associated viral (AAV) vectors to increase Perm1 e

15 of the new millennium it became evident that adeno-associated viral (AAV)-mediated gene transfer to t

16 shown that in vitro transduction with bovine adeno-associated viral (BAAV) vectors restores connexin

17 delivered to HSA(LR) mice using recombinant adeno-associated viral (rAAV) vectors injected intraveno

18 cute pharmacological studies and longer-term adeno-associated viral knockdown experiments indicate th

19 ort a truncated RCas9 system compatible with adeno-associated viral packaging.

20 helial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce s

21 eatment of affected forelimb muscles with an adeno-associated viral vector (AAV) encoding human Neuro

22 ered using a clinically approved serotype of adeno-associated viral vector (AAV1).

23 Recent clinical breakthroughs in recombinant adeno-associated viral vector (rAAV)-based gene therapy

24 Myh6, Sav1, and Tbx20, using a cardiotropic adeno-associated viral vector 9.

25 a-synuclein 1-120 and rats injected with the adeno-associated viral vector carrying wild-type human a

26 with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for

27 em that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous d

28 cortical neuron cultures transduced with an adeno-associated viral vector driving the GCaMP6f report

29 genic retinal detachment for the delivery of adeno-associated viral vector encoding Rab Escort Protei

30 mal area was reduced after treatment with an adeno-associated viral vector expressing a short hairpin

31 itude changes following administration of an adeno-associated viral vector expressing Flag-micro-dyst

32 We inject an adeno-associated viral vector expressing the inhibitory

33 To study this, we administered an adeno-associated viral vector expressing VEGF-B or contr

34 r fluorescent tag alone by using recombinant adeno-associated viral vector in the liver of three mous

35 in vivo for their functional properties with adeno-associated viral vector libraries and identify car

36 Ang-(1-9) was delivered by adeno-associated viral vector via single tail vein injec

37 An adeno-associated viral vector was also used to reconstit

38 ear of Ush1c c.216G>A mice using a synthetic adeno-associated viral vector, Anc80L65, shown to transd

39 otent shRNA, S1, which, when delivered by an adeno-associated viral vector, effectively inhibits HBV

40 mouse model of retinal degeneration using an adeno-associated viral vector.

41 3 signaling axis, we used local injection of adeno-associated viral vectors (AAVs) encoding ligand-sp

42 kers was present in 2 patients who underwent adeno-associated viral vectors (serotype 2)-mediated NGF

43 feasibility of gene therapy via recombinant adeno-associated viral vectors as a viable treatment app

44 Adeno-associated viral vectors can be used as a platform

45 We injected adeno-associated viral vectors coding for Cre-dependent

46 and cynomolgus macaques were transduced with adeno-associated viral vectors encoding hNTCP and subseq

47 C57BL/6 mice were i.v. injected with adeno-associated viral vectors encoding murine IL-12 or

48 LRRK2 rats were injected intracranially with adeno-associated viral vectors expressing human alpha-sy

49 his study seeks to enhance the capability of adeno-associated viral vectors for therapeutic gene deli

50 vivo intramuscular injections of recombinant adeno-associated viral vectors harbouring a myosin trans

51 and finally, the use of gene transfer using adeno-associated viral vectors to deliver bNAbs.

52 In this study, we used adeno-associated viral vectors to elevate circulating le

53 s) were ovariectomized, and, 14 weeks later, adeno-associated viral vectors were used to express ERal

54 iver viral envelopes) and self-complementary adeno-associated viral vectors, serotype-9 (scAAV-9) in

55 nd chemokines, were individually cloned into adeno-associated viral vectors.

56 to adult midbrain dopaminergic neurons using adeno-associated viral vectors.

57 Thus, we developed an adeno-associated viral-based strategy to selectively tar

58 Adeno-associated virus (AAV) -delivered gene therapy has

59 We applied STN-DBS in an adeno-associated virus (AAV) 1/2-driven human mutated A5

60 finger nuclease mRNA via electroporation and adeno-associated virus (AAV) 6 delivery of donor constru

61 , we assessed the therapeutic efficacy of an adeno-associated virus (AAV) 9-mbetagal vector infused s

62 ession in 1-month old mdx:utr (-/-) mice via adeno-associated virus (AAV) 9-mediated RNA interference

63 The Rep68 protein from adeno-associated virus (AAV) combines a DNA binding and

64 c applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle.

65 ese cytokines in a murine model of CHB using adeno-associated virus (AAV) delivery.

66 g RNP delivery with naturally recombinogenic adeno-associated virus (AAV) donor vectors enables site-

67 roteostasis in AMD, we delivered recombinant adeno-associated virus (AAV) encoding Abeta42 and Abeta4

68 Adeno-associated virus (AAV) entry is determined by its

69 Stable delivery of adeno-associated virus (AAV) expressing cKL to diabetic

70 fective therapy for corneal vascularization, adeno-associated virus (AAV) gene therapy, exploiting a

71 al cord via intrathecal administration of an adeno-associated virus (AAV) gene transfer vector signif

72 Adeno-associated virus (AAV) has become the vector of ch

73 Adeno-associated virus (AAV) has been shown to transduce

74 Gene delivery vectors based on adeno-associated virus (AAV) have been utilized in a lar

75 CRISPR-Cas9 delivery by adeno-associated virus (AAV) holds promise for gene ther

76 However, in vivo delivery of mAgrin via adeno-associated virus (AAV) into FKRP mutant mice was u

77 Adeno-associated virus (AAV) is a replication-deficient

78 Adeno-associated virus (AAV) is frequently used to manip

79 therapy using nonintegrating viruses such as adeno-associated virus (AAV) is not optimal in this sett

80 The life cycle of the human parvovirus adeno-associated virus (AAV) is orchestrated by four Rep

81 Intracellular transport of recombinant adeno-associated virus (AAV) is still incompletely under

82 Adeno-associated virus (AAV) is the only eukaryotic viru

83 Delivery by adeno-associated virus (AAV) of clustered regularly inte

84 Vectors based on adeno-associated virus (AAV) present a number of advanta

85 ating protein (AAP) is a recently discovered adeno-associated virus (AAV) protein that promotes capsi

86 e (ZFN) mRNA with donor template delivery by adeno-associated virus (AAV) serotype 6 vectors directs

87 Many adeno-associated virus (AAV) serotypes efficiently trans

88 placement of SDS-PAGE for purity analysis of adeno-associated virus (AAV) therapeutic products of dif

89 Using adeno-associated virus (AAV) to inhibit the calcineurin-

90 The ability to target the adeno-associated virus (AAV) to specific types of cells,

91 We have previously shown that the adeno-associated virus (AAV) variant, ShH10, transduces

92 previously reported compassionate use of an adeno-associated virus (AAV) vector containing the human

93 ateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing the RPE65

94 The adeno-associated virus (AAV) vector gene delivery system

95 ssion in the dorsal striatum, we injected an adeno-associated virus (AAV) vector producing a short ha

96 d for IDUA production and function following adeno-associated virus (AAV) vector transduction of MPS1

97 dministered a single intravenous dose of the adeno-associated virus (AAV) vector, AAV-BR1-CAG-NEMO, d

98 ed in the brains of transgenic mice using an adeno-associated virus (AAV) vector, decreased parenchym

99 age it with two gRNAs in a single functional adeno-associated virus (AAV) vector.

100 ) directed against CVB3 were delivered by an adeno-associated virus (AAV) vector.

101 Adeno-associated virus (AAV) vectors are currently the l

102 ants identified Anc80L65 from a set of other adeno-associated virus (AAV) vectors as a potent vector

103 reprogramming of MFs into hepatocytes using adeno-associated virus (AAV) vectors expressing hepatic

104 the astrocytic CN/NFAT pathway in rats using adeno-associated virus (AAV) vectors expressing the astr

105 Herein, we review the use of adeno-associated virus (AAV) vectors for delivery of HIV

106 We investigated adeno-associated virus (AAV) vectors for gene delivery t

107 Immune responses in gene therapy with adeno-associated virus (AAV) vectors have been the objec

108 Adeno-associated virus (AAV) vectors have been used succ

109 Adeno-associated virus (AAV) vectors have made great pro

110 eover, cardiac overexpression of HMGB1 using adeno-associated virus (AAV) vectors induced inflammatio

111 Here, we created several adeno-associated virus (AAV) vectors to deliver genes th

112 itution, Y704A, near the 2-fold interface of adeno-associated virus (AAV) was defective for transcrip

113 We combined the adeno-associated virus (AAV) with the Cre-loxP site-spec

114 retrograde functionality into the capsid of adeno-associated virus (AAV), a vector that has shown pr

115 n mouse are systematically investigated with adeno-associated virus (AAV), an anterograde viral trace

116 ere we present two methods for radiolabeling adeno-associated virus (AAV), one of the most commonly u

117 ct design, RAM can be packaged into a single adeno-associated virus (AAV), providing great versatilit

118 teps in the life cycle of a human virus, the adeno-associated virus (AAV), that causes no known disea

119 Second, we package the library into adeno-associated virus (AAV), thereby allowing delivery

120 Adeno-associated virus (AAV)-Cre-mediated Vgf ablation i

121 Here, we describe a lineage-specific, adeno-associated virus (AAV)-derived endogenous viral el

122 ticospinal neurons specifically by injecting adeno-associated virus (AAV)-expressing Cre-dependent DR

123 Adeno-associated virus (AAV)-hepcidin was injected into

124 We prepared adeno-associated virus (AAV)-IFN-gamma and AAV-IL-4 and

125 Here we report that a system of adeno-associated virus (AAV)-mediated clustered regularl

126 we report a genome editing approach in which adeno-associated virus (AAV)-mediated CRISPR/Cas9 delive

127 enerated mice with elevated expression using adeno-associated virus (AAV)-mediated gene delivery.

128 We use adeno-associated virus (AAV)-mediated gene editing to kn

129 While the recent success of adeno-associated virus (AAV)-mediated gene therapy in cl

130 Adeno-associated virus (AAV)-mediated gene therapy is cu

131 We sought to develop an efficient adeno-associated virus (AAV)-mediated RNAi gene therapy

132 plore the therapeutic potential of naked and adeno-associated virus (AAV)-packaged AONs in vitro and

133 ST input, and the right CST was treated with adeno-associated virus (AAV)-Sox11 or AAV-EBFP control,

134 lar dystrophy, dystrophin restoration during adeno-associated virus (AAV)-U7-mediated exon-skipping t

135 irect intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau a

136 These aptayzmes efficiently regulated adeno-associated virus (AAV)-vectored transgene expressi

137 essed CRY in SCN of Cry-deficient mice using adeno-associated virus (AAV).

138 he efficient delivery of donor template with adeno-associated virus (AAV).

139 c efficacy of telomerase activation by using adeno-associated virus (AAV)9 gene therapy vectors carry

140 To address this, we developed a novel adeno-associated virus (AAV-GLP-1R) that utilizes short

141 ta pathology, we investigated the effects of adeno-associated virus (AAV2/1)-mediated expression of I

142 A mitochondria-targeted adeno-associated virus (MTS-AAV) containing the mutant h

143 At day 28, recombinant adeno-associated virus (rAAV) (5 x 10(12) viral particle

144 We administered recombinant adeno-associated virus (rAAV) expressing miS1, an artifi

145 Recombinant adeno-associated virus (rAAV) is an attractive tool for

146 highly efficient CRISPR directed recombinant Adeno-Associated Virus (rAAV) mediated gene targeting ap

147 that gene therapy mediated by a recombinant adeno-associated virus (rAAV) vector expressing human G6

148 n mice receiving high doses of a recombinant adeno-associated virus (rAAV) vector expressing shRNAs (

149 that the non-tumor-bearing (NT), recombinant adeno-associated virus (rAAV) vector-treated GSD-Ia mice

150 lionic or intrathecal injection, recombinant adeno-associated virus (rAAV) vectors can also infect se

151 tional microdystrophin genes and recombinant adeno-associated virus (rAAV) vectors is an attractive s

152 ne therapy in G6pt-/- mice using recombinant adeno-associated virus (rAAV) vectors, directed by eithe

153 Here we perform recombinant adeno-associated virus (rAAV)-mediated promoterless gene

154 d safety of gene therapy through infusion of adeno-associated virus 1 (AAV1)/SERCA2a in patients with

155 time mice were intracranially injected with adeno-associated virus 1 expressing murine IL-6 (AAV1-mI

156 Adeno-associated virus 2 (AAV2) and adenovirus 5 (Ad5) a

157 been studied mostly in the dependoparvovirus adeno-associated virus 2 (AAV2) and the protoparvovirus

158 Adeno-associated virus 2 (AAV2) depends on the simultane

159 che for either virus to replicate.IMPORTANCE Adeno-associated virus 2 (AAV2) differs from most other

160 On the other hand, adeno-associated virus 2 (AAV2) is a helper-dependent de

161 ector, rAAV2/HBoV1, in which the recombinant adeno-associated virus 2 (rAAV2) genome is pseudopackage

162 Both adeno-associated virus 2 and adenovirus 5 are currently

163 Suppression of Sema3e using adeno-associated virus 2 carrying short hairpin RNA targ

164 efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the

165 lso was performed in mice given infusions of adeno-associated virus 6-NF-kappaB-luciferase, to assess

166 d by live imaging of mice given infusions of adeno-associated virus 6-NF-kappaB-luciferase.

167 ntrols, were given injections of recombinant adeno-associated virus 8 vector that expressed the prima

168 In proof-of-concept experiments, we used Adeno-Associated Virus 9 (AAV9) to deliver single-guide

169 Similarly, adeno-associated virus 9 (AAV9)-mediated restoration of

170 or JNCL by generating two self-complementary adeno-associated virus 9 (scAAV9) constructs to address

171 livery approach using two self-complementary adeno-associated virus 9 (scAAV9) constructs to address

172 In the present study, we delivered adeno-associated virus 9 carrying green fluorescent prot

173 holesterolaemia liver chimeric mice using an adeno-associated virus 9-based gene therapy and restore

174 -type levels in a mouse model of I/R, as did adeno-associated virus 9-mediated ATF6 overexpression.

175 Adeno-associated virus 9-mediated Cdk5 inhibitory peptid

176 D1-MSNs versus D2-MSNs using a Cre-inducible adeno-associated virus and Cre lines during cocaine cond

177 urb a specific molecular interaction between adeno-associated virus and its host cell, which can be r

178 Here we designed a hybrid adeno-associated virus and phage (AAVP) vector displayin

179 therapy include the emergence of recombinant adeno-associated virus as the vector of choice, capsid e

180 We introduced adeno-associated virus carrying the gene for either the

181 We injected recombinant adeno-associated virus containing the CRRY coding sequen

182 we lineage-labeled hepatocytes by injecting adeno-associated virus containing thyroxine-binding glob

183 iabetes and two models of type 2 diabetes by adeno-associated virus delivery of renin (ReninAAV).

184 BALB/c mice treated with adeno-associated virus encoding the BL6 BAG3 variant (Il

185 ta signaling in the substantia nigra through adeno-associated virus expressing a constitutively activ

186 With neonatal administration of adeno-associated virus expressing arginase, there is nea

187 g 5-HT system by stereotaxic injection of an adeno-associated virus expressing Cre recombinase (AAV-C

188 of stress-susceptible or mice injected with adeno-associated virus expressing shRNA against Cldn5 ca

189 e that overproduce sclerostin as a result of adeno-associated virus expression from the liver.

190 rate that particular groups of drugs enhance adeno-associated virus gene delivery by unknown mechanis

191 animal models to determine if they increased adeno-associated virus gene delivery.

192 tential for FDA-approved drug enhancement of adeno-associated virus gene therapy, which could result

193 Additionally, adeno-associated virus has demonstrated outstanding pote

194 Adeno-associated virus IL-12-treated mice developed hist

195 constructs in mouse rod photoreceptors using adeno-associated virus in Xenopus laevis rod photorecept

196 ng reporter genes into the safe-harbor locus adeno-associated virus integration site 1 in human embry

197 In addition, introduction of 3xMyc-FXR1 via adeno-associated virus into mice leads to the redistribu

198 We used a DREADD, hM3Dq, administered via adeno-associated virus into the LC under a synthetic pro

199 s when the packaging capacity of recombinant adeno-associated virus is limited while tissue-specific

200 Systemic delivery of dCas9/gRNA by adeno-associated virus led to reductions in pathological

201 n via stereotactic hippocampal injections of adeno-associated virus particles in mutant hAPP Tg mouse

202 teral, intranigral injections of recombinant adeno-associated virus pseudotype 2/5 to overexpress wil

203 Adeno-associated virus receptor (AAVR) (also named KIAA0

204 pression of DISC1 in the hippocampus with an adeno-associated virus reduced the levels of BACE1, solu

205 Hepatic arginase 1 gene therapy using adeno-associated virus rescued nearly all these abnormal

206 Specifically, we labeled adeno-associated virus serotype 10 expressing the coding

207 teral dorsal amygdala Ce-region infusions of adeno-associated virus serotype 2 containing the CRF con

208 single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding

209 rphysiological doses of MIS, using either an adeno-associated virus serotype 9 (AAV9) gene therapy ve

210 acy of gene therapy for NPC1, we constructed adeno-associated virus serotype 9 (AAV9) vectors to deli

211 h SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying SMN complemen

212 a potent inducer of premature senescence, by adeno-associated virus serotype 9 gene transfer, resulte

213 CRISPR/Cas9-based cardiac gene editing using adeno-associated virus serotype 9 to deliver a single sh

214 In vivo, AAV9 (adeno-associated virus serotype 9)-mediated cardiac over

215 Using intrathecal adeno-associated virus serotype 9-based delivery, the gl

216 ic implications, we found that prior in vivo Adeno-associated virus serotype 9-mediated gene delivery

217 METHODS AND Using an in vivo Adeno-associated virus serotype 9-mediated gene transfer

218 the heart of 7-month-old SJ13 mice using an adeno-associated virus serotype-9 Cre recombinase vector

219 Cardiac-specific overexpression of FGF16 via adeno-associated virus subtype 9 (AAV9) in the mutant he

220 g within the VTA, we delivered Cre-inducible adeno-associated virus that drives the expression of flu

221 Here we describe a novel recombinant adeno-associated virus that restricts gene expression to

222 c retrograde tracing to label the inputs and adeno-associated virus to trace axonal projections, we i

223 rat spinal cord after dorsal root crush and adeno-associated virus transgene expression in dorsal ro

224 ene expression using aerosolized delivery of adeno-associated virus type 1 (AAV1) in a large animal m

225 Vectors based on adeno-associated virus type 2 (AAV2) are powerful tools

226 Moreover, adeno-associated virus type 2-mediated IGF2 overexpressi

227 G of CXCL10(-/-) mice, using the neurotropic adeno-associated virus type 8 (AAV8) vector, boosted the

228 ty and tolerability of escalated doses of an adeno-associated virus vector (AAV) expressing a normal

229 cus aureus) and guide RNA constructs into an adeno-associated virus vector and systemically delivered

230 t NOD scid gamma (NSG) mice by the use of an adeno-associated virus vector, followed by engraftment o

231 Intrahippocampal injections of adeno-associated virus vectors containing the astrocyte-

232 we show that expression of these genes from adeno-associated virus vectors in C57BL/6 mice is able t

233 gnaling in a common mouse model of AD, using adeno-associated virus vectors normalized glutamate sign

234 human patients, and gene augmentation using adeno-associated virus vectors robustly sustained the re

235 ts within the packaging limit of recombinant adeno-associated virus vectors that have been shown to b

236 assemblies, similar to the best recombinant adeno-associated virus vectors.

237 In this study, adeno-associated virus was used to deliver the clustered

238 n of c-Fos using photoreceptor-specific AAV (adeno-associated virus)-hRK (human rhodopsin kinase)-sh_

239 We investigated whether exosome-associated adeno-associated virus, (exo-AAV) enabled broad retinal

240 han HepG2 cells after HBV genome delivery by adeno-associated virus, and stable expression of NTCP in

241 ntify integrations of murine leukemia virus, adeno-associated virus, Tol2 transposons or Ac/Ds transp

242 AMT-060 combines an adeno-associated virus-5 (AAV5) vector with a liver-spec

243 in postnatal muscle tissue in vivo, we used adeno-associated virus-9 (AAV9) to deliver gene-editing

244 Systemic injection of adeno-associated virus-BAG3(Ile81) (n=9), but not BAG3(M

245 e treatment of a mouse model of OPMD with an adeno-associated virus-based gene therapy combining comp

246 from transgenic mice and from WT mice after adeno-associated virus-based gene transfer of ChR2.

247 Leading the way has been the use of adeno-associated virus-based strategies for factor IX ge

248 ntramuscular administration of a recombinant adeno-associated virus-based vector (rAAV vector) expres

249 d deep sequencing results confirmed that our adeno-associated virus-CRISPR/Cas9 strategy was very eff

250 Adeno-associated virus-CYP46A1 infection in R6/2 mice al

251 e, using a combination of electrophysiology, adeno-associated virus-delivered fluorescent proteins, a

252 Here, we show that adeno-associated virus-driven expression of progranulin

253 Moreover, they demonstrated that adeno-associated virus-mediated (AAV-mediated) delivery

254 n the R6/2 Huntington's disease mouse model, adeno-associated virus-mediated delivery of CYP46A1 into

255 n CYP46A1 expression in the striatum, via an adeno-associated virus-mediated delivery of selective sh

256 ethylmalonic encephalopathy, liver-targeted adeno-associated virus-mediated ETHE1 gene transfer dram

257 llel, we explored the effects of recombinant adeno-associated virus-mediated expression of Abeta38 an

258 Adeno-associated virus-mediated expression of glucocereb

259 llowing high over-expression of WT hAIPL1 by adeno-associated virus-mediated gene delivery, which was

260 u scFvs and tested their efficacy in vivo by adeno-associated virus-mediated gene transfer to the bra

261 ubcellular localizations of each fragment by adeno-associated virus-mediated gene transfer.

262 Three approaches were compared: 1) adeno-associated virus-mediated in utero transfer of the

263 Adeno-associated virus-mediated increase in AKT activati

264 Efficient adeno-associated virus-mediated knockdown of ZSCAN21 in

265 ma cells and in mice by peptide injection or adeno-associated virus-mediated overexpression.

266 Adeno-associated virus-mediated Snapin overexpression in

267 We also show that targeted adeno-associated virus-mediated suppression of claudin-5

268 Adeno-associated virus-mediated targeting of RGMa to mou

269 Using a novel adeno-associated virus-mediated technique to label AII a

270 In contrast, transgenic or adeno-associated virus-mediated TNFAIP3 gene delivery in

271 Here we developed an adeno-associated virus-mediated, autochthonous genetic C

272 Adeno-associated virus-progranulin also corrected lysoso

273 The adeno-associated virus-progranulin vector only transduce

274 Adeno-associated virus-Sesn2 was delivered to aged heart

275 R induced by intraparenchymal delivery of an adeno-associated virus-short hairpin RNA construct was s

276 We used mice with a mutation in Npas2 and adeno-associated virus-short hairpin RNA mediated knockd

277 liver-specific overexpression of human ZIP8 (adeno-associated virus-ZIP8 [AAV-ZIP8]) resulted in incr

278 ll enough to be packaged efficiently into an adeno-associated virus.

279 er a single systemic delivery of recombinant adeno-associated virus.

280 ckout mice and mice injected with 3xMyc-FXR1 adeno-associated virus.

281 nd a donor template delivered by recombinant adeno-associated virus.

282 he murine heart was performed by means of an adeno-associated virus.

283 ected strategies based on SNTRVAP-displaying adeno-associated virus/phage (AAVP) particles in mice be

284 R-155) in an in vivo model of PD produced by adeno-associated-virus-mediated expression of alpha-syn.

285 The adeno-associated viruses (AAV) are promising therapeutic

286 Adeno-associated viruses (AAV) are thought to spread thr

287 In the case of recombinant adeno-associated viruses (AAV), proteasome inhibitors ar

288 Here, we discovered that adeno-associated viruses (AAV1 and AAV9) exhibit anterog

289 Adeno-associated viruses (AAVs) are attractive gene ther

290 Adeno-associated viruses (AAVs) are commonly used for in

291 Recombinant adeno-associated viruses (AAVs) are promising vectors fo

292 Adeno-associated viruses (AAVs) currently are being deve

293 The use of adeno-associated viruses (AAVs) has proven to be an effe

294 sting neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) pose a major, unresolved

295 The adeno-associated viruses (AAVs), which are being develop

296 Recombinant adeno-associated viruses (rAAVs) are commonly used vehic

297 We treated mice with either adeno-associated viruses encoding a control (green fluor

298 particle-mediated delivery of Cas9 mRNA with adeno-associated viruses encoding a sgRNA and a repair t

299 cargo including nucleic acids, polypeptides, adeno-associated viruses, and nanodots.

300 l vectors can package larger transgenes than adeno-associated viruses, yet lentiviral vectors remain